(Q38137849)

29 August 2017

title

Pharmacologic therapy that simulates conditioning for cardiac ischemic/reperfusion injury (English)

1 reference

29 August 2017

1 reference

1 reference

2

Derek M Yellon

1 reference

29 August 2017

1

Vivek Sivaraman

1 reference

29 August 2017

publication date

13 September 2013

1 reference

Journal of Cardiovascular Pharmacology and Therapeutics

29 August 2017

published in

1 reference

29 August 2017

volume

19

1 reference

29 August 2017

issue

1

1 reference

29 August 2017

page(s)

83-96

1 reference

Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Remote ischaemic preconditioning: underlying mechanisms and clinical application.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Myocardial ischemia-reperfusion injury: a neglected therapeutic target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Calcium-mediated cell death during myocardial reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Ischemia and reperfusion--from mechanism to translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Myocardial reperfusion injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Preconditioning the Myocardium: From Cellular Physiology to Clinical Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Transitory activation of AMPK at reperfusion protects the ischaemic-reperfused rat myocardium against infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Protein kinase C-epsilon is responsible for the protection of preconditioning in rabbit cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery fo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

AMP579 is revealed to be a potent A2b-adenosine receptor agonist in human 293 cells and rabbit hearts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Limitation of infarct size in rabbit hearts by the novel adenosine receptor agonist AMP 579 administered at reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Cardioprotective properties of bradykinin: role of the B(2) receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT(1)-receptor antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Pretreatment with ramiprilat induces cardioprotection against free radical injury in guinea-pig isolated heart: involvement of bradykinin, protein kinase C and prostaglandins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Effects of a protocol of ischemic postconditioning and/or captopril in hearts of normotensive and hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Angiotensin-converting enzyme inhibition enhances a subthreshold stimulus to elicit delayed preconditioning in pig myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

The anti-inflammatory effect of bradykinin preconditioning in coronary artery bypass grafting (bradykinin and preconditioning).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Assessment of ventricular remodeling in heart failure clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Myocardial protection with enalaprilat in patients unresponsive to ischemic preconditioning during percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Remifentanil reduces the release of biochemical markers of myocardial damage after coronary artery bypass surgery: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Remifentanil post-conditioning attenuates cardiac ischemia-reperfusion injury via kappa or delta opioid receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Role of opioids in acute and delayed preconditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Cardiovascular protective properties of incretin-based therapies in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Cardioprotective effects of incretin during ischaemia-reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Mechanisms of atrial natriuretic peptide secretion from the atrium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Cardiac natriuretic peptides: from basic discovery to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Atrial natriuretic peptide prevents the mitochondrial permeability transition pore opening by inactivating glycogen synthase kinase 3β via PKG and PI3K in cardiac H9c2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Hypoxia-inducible factor as a therapeutic target for cardioprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

New avenues of exploration for erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

A single dose of erythropoietin in ST-elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Endogenous erythropoietin and a single bolus of 40,000 IU of epoetin alpha do not protect the heart from ischaemia-reperfusion injury during extracorporeal circulation for cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Evaluation of the effect of one large dose of erythropoietin against cardiac and cerebral ischemic injury occurring during cardiac surgery with cardiopulmonary bypass: a randomized double-blind placebo-controlled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Erythropoietin Prevention Trial of Coronary Restenosis and Cardiac Remodeling After ST-Elevated Acute Myocardial Infarction (EPOC-AMI) - A Pilot, Randomized, Placebo-Controlled Study -

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction - randomized controlled pilot trial of EPO/AMI-1 study -.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

A single-center prospective randomized controlled trial evaluating the safety and efficacy of IntraCoronary Erythropoietin delivery BEfore Reperfusion: gauging infarct size in patients with acute ST-segment elevation myocardial infarction. Study des

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

The first three domains of the insulin receptor differ structurally from the insulin-like growth factor 1 receptor in the regions governing ligand specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Role of insulin in the anti-apoptotic effect of glucose-insulin-potassium in rabbits with acute myocardial ischemia and reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Volatile anesthetics protect the ischemic rabbit myocardium from infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Effects of enflurane, isoflurane, sevoflurane and desflurane on reperfusion injury after regional myocardial ischaemia in the rabbit heart in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Anaesthesia and myocardial ischaemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Recovery of LV contractility in man is enhanced by preischemic administration of enflurane.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Choice of primary anesthetic regimen can influence intensive care unit length of stay after coronary surgery with cardiopulmonary bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Preconditioning with sevoflurane decreases PECAM-1 expression and improves one-year cardiovascular outcome in coronary artery bypass graft surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

A comparison of volatile and non volatile agents for cardioprotection during on-pump coronary surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Phosphodiesterase 5 inhibitors: are they cardioprotective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Sildenafil: a review of its use in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Cardiac uses of phosphodiesterase-5 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

S-nitrosothiols cause prolonged, nitric oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Nitric oxide is a preconditioning mimetic and cardioprotectant and is the basis of many available infarct-sparing strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Protection by remote ischemic preconditioning during coronary artery bypass graft surgery with isoflurane but not propofol - a clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Nitroglycerin does not interfere with protection by remote ischemic preconditioning in patients with surgical coronary revascularization under isoflurane anesthesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Statin loading for acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Failure to recapture cardioprotection with high-dose atorvastatin in coronary artery bypass surgery: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

The roles of PKCdelta and epsilon isoenzymes in the regulation of myocardial ischaemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

The divergent roles of protein kinase C epsilon and delta in simulated ischaemia-reperfusion injury in human myocardium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Protein kinase C, an elusive therapeutic target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Use of nicorandil in cardiovascular disease and its optimization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Opening of mitochondrial K(ATP) channels triggers the preconditioned state by generating free radicals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Cardioprotective effects of nicorandil in patients undergoing on-pump coronary artery bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Mitochondrial cyclophilin-D as a critical mediator of ischaemic preconditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Mitochondrial permeability transition pore as a target for cardioprotection in the human heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Effect of cyclosporine on reperfusion injury in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Platelet P2Y₁₂ blockers confer direct postconditioning-like protection in reperfused rabbit hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Antagonism of P2Y12 or GPIIb/IIIa receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat hearts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

High-dose erythropoietin in patients with acute myocardial infarction: A pilot, randomised, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413499973

21 January 2018

Identifiers

DOI

10.1177/1074248413499973

1 reference

29 August 2017

1 reference